Eli Aharoni
Chief Tech/Sci/R&D Officer bij SAMSARA VISION, INC.
Profiel
Eli Aharoni is currently working as Vice President-Research & Development, GM at Samsara Vision, Inc. He previously worked as Vice President-Finance at Acceleron Pharma, Inc. He completed his undergraduate degree from Technion-Israel Institute of Technology.
Actieve functies van Eli Aharoni
| Bedrijven | Functie | Begin |
|---|---|---|
| SAMSARA VISION, INC. | Chief Tech/Sci/R&D Officer | 01-01-2001 |
Eerdere bekende functies van Eli Aharoni
| Bedrijven | Functie | Einde |
|---|---|---|
| ACCELERON PHARMA INC. | Director of Finance/CFO | - |
Opleiding van Eli Aharoni
| Technion-Israel Institute of Technology | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Samsara Vision, Inc.
 Samsara Vision, Inc. Medical SpecialtiesHealth Technology Samsara Vision, Inc. engages in the business of research, development, manufacturing, and marketing proprietary implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders. It operates under the United States and Other geographical segments. The company was founded by Isaac Lipshitz, David Lifschitz, Yossi Gross, Boaz Lifschitz, and Eyal Lifschitz in 1997 and is headquartered in Far Hills, NJ. | Health Technology |
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
